Premium
Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis
Author(s) -
Hong Xia,
Jiang Shan,
Marmolejo Nancy,
Vangipuram Ramya,
RamosRojas Elmira,
Yuan Yulin,
Lin ZuanTao,
Li Yaxi,
Qiu Jingyi,
Xing Yikun,
Haley Christopher,
Tyring Stephen K.,
Wu Tianfu
Publication year - 2018
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13727
Subject(s) - psoriasis , medicine , psoriatic arthritis , psoriasis area and severity index , biomarker , area under the curve , vascular endothelial growth factor , receiver operating characteristic , antibody microarray , gastroenterology , antibody , immunology , vegf receptors , biochemistry , chemistry
To discover novel biomarkers of psoriasis, a target‐specific antibody array screening of serum samples from psoriasis patients was initially performed. The results revealed that vascular endothelial growth factor receptor 3 ( VEGFR ‐3) was significantly elevated in the sera of psoriasis patients, compared to healthy controls. Next, ELISA validation studies in a larger cohort of psoriasis patients (N = 73) were conducted, which confirmed that serum VEGFR ‐3 was indeed significantly increased in patients with psoriasis compared to healthy controls ( P < 0.001). Furthermore, receiver operating characteristic curve analysis demonstrated that serum VEGFR ‐3 exhibited potential in distinguishing healthy controls from psoriasis patients: area under the curve = 0.85, P < 0.001. In addition, serum levels of VEGFR ‐3 were correlated with Psoriasis Area Severity Index scores ( R = 0.32, P = 0.008) in psoriasis patients. Interestingly, serum VEGFR ‐3 levels were significantly elevated in psoriatic arthritis compared to non‐psoriatic arthritis ( P = 0.026). A pilot longitudinal study demonstrated that serum levels of VEGFR ‐3 could reflect disease progression in psoriasis. Collectively, serum VEGFR ‐3 may have a clinical value in monitoring disease activity of psoriasis.